A61K 45 - Medicinal preparations containing active ingredients not provided for in groups

Patents for A61K 45 - Medicinal preparations containing active ingredients not provided for in groups (115,020)
12/2006
12/20/2006	EP1372665B1 Hormone replacement therapy method and its administration form
12/20/2006	EP1357935B1 Reducing side effects of chemotherapy in cancer patients
12/20/2006	EP1353696B1 Combinations of peroxisome proliferator-activated receptor (ppar) activator(s) and sterol absorption inhibitor(s) and treatments for vascular indications
12/20/2006	EP1317537B1 G-csf analog compositions and methods
12/20/2006	EP1146891B1 Therapy of restenosis and atherosclerosis with a soluble vegf receptor and angiopoeitin-1
12/20/2006	EP1135477B1 Humanized monoclonal integrin antibodies
12/20/2006	EP1027027B1 Use of amylin, adrenomedullin and analogues thereof for treating cartilage defects
12/20/2006	EP0858336B1 Method and pharmaceutical composition for regulating lipid concentration
12/20/2006	EP0764022B1 Agonists and antagonists of the nicotinic acetylcholine receptors of insects to control endoparasites
12/20/2006	CN1882508A Process for preparing water soluble diterpenes and their applications
12/20/2006	CN1882352A Pharmaceutical composition comprising a zinc-hyaluronate complex for the treatment of multiple sclerosis
12/20/2006	CN1882350A Method for controlling angiogenesis in animals
12/20/2006	CN1882342A Use of CHK1 inhibitors to control cell proliferation
12/20/2006	CN1882328A Methods and compositions for the treatment of helicobacter pylori-associated diseases using endoperoxide bridge-containing compounds
12/20/2006	CN1879889A Kidney-targeted medicine vector and the formed prodrug, preparation method and uses
12/20/2006	CN1879885A Stomach dissolution type pharmaceutical composition and its preparation method
12/20/2006	CN1879884A Synergistic therapeutic compositions and methods
12/20/2006	CN1879883A Preparation method of medicine for treating male baldness and its clinical application
12/20/2006	CN1879882A Combine injection formulation
12/20/2006	CN1879624A 5-ht 1a receptor subtype agonists
12/20/2006	CN1879620A A sustained release injection containing penicillins antibiotic and application thereof
12/20/2006	CN1879608A Bioadhesive progressive hydration tablets
12/20/2006	CN1879604A An antibiotics-containing sustained releasing injection and application thereof
12/20/2006	CN1879507A Water containing soluble fiber
12/20/2006	CN1290866C Anthrax toxin acceptor ATR-Fc fusion protein
12/20/2006	CN1290848C Beta-amino tetrahydroimidazo (1,2-a) pyrazines and ahydrotrioazolo (4,3-a) pyrazines as dipeptidyl peptidase inhibitors for the treatment or prevention of diabetes
12/20/2006	CN1290847C Aza-arylpiperazines
12/20/2006	CN1290833C N- ((3-oxo2, 3-dihydro-1H-isoindol-1-yl) acetyl) guanidine derivatives as NHE-1 inhibitors for the treatment of infarction and angina pectoris
12/20/2006	CN1290581C Remedy for hypertension
12/20/2006	CN1290504C Combination comprising combretastatin and anticancer agents
12/20/2006	CN1290501C Pharmaceutically active isoindoline derivatives
12/20/2006	CN1290500C Retroviral protease inhibitor combinations
12/19/2006	USRE39436 Interventions to mimic the effects of calorie restriction
12/19/2006	USRE39433 Therapeutic agents as cytokine antagonists and agonists
12/19/2006	US7151117 Administering a X-ray contrast media selected from iotrolan and iodixannol to an eye of a mammal suffering from allergic conjunctivitis and allergic rhinitis to decrease in histamine release; side effect reduction
12/19/2006	US7150986 Adhesion to mucous membranes; cell proliferation; prevention, therapy of digestion diseases
12/19/2006	US7150983 Modified proteolytic enzyme for treatment of osteoarthritis
12/19/2006	US7150883 Liposome suspension forms spontaneously upon adding a diacylglycerol-PEG lipid to an aqueous solution when the lipid has appropriate packing parameters and the adding occurs above the melting temperature of the lipid
12/19/2006	US7150880 Drink for athletes; creatine plays a pivotal role in the regulation and homeostasis of skeletal muscle energy metabolism
12/19/2006	US7150871 Treatment of acute lung injury, fibrosis and metastasis with antagonists of αvβ6
12/19/2006	US7150869 Gene therapy; cytokine complex; anticancer agent
12/19/2006	CA2301577C Glucose-containing preparation
12/19/2006	CA2168659C Substituted azaindolylidene compounds and process for their preparation
12/19/2006	CA2155200C Use of topical anesthetics for the treatment of eosinophil-associated diseases
12/14/2006	WO2006133391A2 Improved treatment for anemia using a hif-alpha stabilising agent
12/14/2006	WO2006132524A1 Means and methods for generating a t cell against an antigen of interest.
12/14/2006	WO2006132440A1 Solid preparation
12/14/2006	WO2006132436A1 Heterocyclic compound
12/14/2006	WO2006132432A1 Therapeutic agent for neurogenic pain
12/14/2006	WO2006132406A1 Npy y2 agonist for use as therapeutic agent for disease accompanied by diarrhea
12/14/2006	WO2006132251A1 Prophylactic/therapeutic agent for adult t cell leukemia
12/14/2006	WO2006132248A1 Method for ubiquitination of runx
12/14/2006	WO2006132196A1 NOVEL PHARMACEUTICAL COMPRISING β3 AGONIST
12/14/2006	WO2006132091A1 Novel triglyceride reducing agent
12/14/2006	WO2006131721A2 Topical ungual formulations
12/14/2006	WO2006131649A2 Use of fumagillin and the derivatives thereof to increase the bioavailability of the macrocyclic lactones
12/14/2006	WO2006131326A2 Novel use of (-)-epigallocatechin gallate
12/14/2006	WO2006105670A8 Combination therapy comprising an n-type calcium channel blocker for the alleviation of pain
12/14/2006	WO2006105168A3 Enhancing immune responses with bacterial exotoxins
12/14/2006	WO2006102061A3 Methods of decreasing calcification
12/14/2006	WO2006097743A3 Method for actvating natural killer cells by tumor cell preparation in vitro
12/14/2006	WO2006017505A3 Pharmaceutical formulations comprising pleconaril for the treatment of airway diseases
12/14/2006	WO2005081870A3 Intervertebral disc repair, methods and devices therefor
12/14/2006	WO2005067627A3 Cosmetic composition and method for retarding hair growth
12/14/2006	WO2004093794A3 Antimicrobial medical articles containing a combination of anti-infective compounds, octoxyclycerin, salicylic acid, and sesquiterpenoids
12/14/2006	WO2001022972A9 Immunostimulatory nucleic acids
12/14/2006	US20060281902 Human signal peptide-containing proteins
12/14/2006	US20060281887 (Meth)acrylate copolymer for use as medical carrier
12/14/2006	US20060281795 Benzinidazole Derivative and Use As AII Receptor Antagonist
12/14/2006	US20060281770 Method of treating an anxiety disorder
12/14/2006	US20060281736 Product comprising at least one phosphatase cdc25 inhibitor combined with at least one other anticancer agent
12/14/2006	US20060281735 Antipsychotic combination therapies and compositions of an alpha-2 adrenergic receptor antagonist and an atypical antipsychotic neuroleptic
12/14/2006	US20060281725 Agents and crystals for improving excretory potency of urinary bladder
12/14/2006	US20060281719 Oestrogen-17-sulphamates as inhibitors of steroid sulphatase
12/14/2006	US20060281694 Procyanidins as antineoplastic agents; topolisomerase, cylooxygenase, and/or lipoxygenase inhibitors; nitric oxide synthase modulators; hypotensive agents; treatment of gingivitis; platelet aggregation modulation
12/14/2006	US20060281693 Renal function improvement
12/14/2006	US20060281679 Human FGF-23 gene and gene expression products
12/14/2006	US20060281146 Novel compositions and methods for the treatment of immune related diseases
12/14/2006	US20060281081 Method of diagnosing colon and gastric cancers
12/14/2006	US20060280810 Disinfecting teat care compositions
12/14/2006	US20060280794 Solid pharmaceutical preparation
12/14/2006	US20060280771 Drug delivery system
12/14/2006	US20060280749 Targeted killing of a cell utilizing a chimeric polypeptide comprising a cell-specific targeting moiety and a signal transduction pathway factor
12/14/2006	US20060280741 Administering the antibody concurrently with an antagonist of IL-1 alpha to treat psoriatic arthritis; arthritis nodosa; seronegative spondylarthropathy, and ulcerative colitis
12/14/2006	US20060280719 An addition polymer from an unsaturated monomer containing a phosphonate group and a phosphinate group separated from eachother by an optionally fluorinated methylene group; treatment of hyperphosphotemia, chronic renal failure, hyperparathyroidism, uremic bone disease, or osteoporosis
12/14/2006	US20060280692 A condensation aerosol for delivery of olanzapine by heating a compositionof olanzapine coated on a solid support to vaporize and condense; the vapor comprising particles of >10 percent by weight of olanzapine and <5 percent by weight of olanzapine degradation products; aerodynamic diameter=<5 microns
12/14/2006	CA2611451A1 Solid preparation
12/14/2006	CA2611446A1 Npy y2 agonist for use as therapeutic agent for disease accompanied by diarrhea
12/14/2006	CA2611201A1 Use of fumagillin and the derivatives thereof to increase the bioavailability of the macrocyclic lactones
12/14/2006	CA2610956A1 Improved treatment for anemia using a hif-alpha stabilising agent
12/14/2006	CA2610605A1 Topical ungual formulations
12/14/2006	CA2610172A1 Heterocyclic compound
12/13/2006	EP1731913A2 Methods and compositions for determining lipid peroxidation levels in oxidant stress syndromes and diseases
12/13/2006	EP1731609A1 Rad51 EXPRESSION INHIBITOR, DRUG CONTAINING THE INHIBITOR AS THE ACTIVE INGREDIENT AND UTILIZATION THEREOF
12/13/2006	EP1731608A1 Marker gene for arthrorheumatism test
12/13/2006	EP1731520A1 Pyrrolo[2,3-d]pyrimidine derivatives which are antagonists of adenosine A1, A2A, and A3
12/13/2006	EP1731183A1 Solid pharmaceutical preparation for dialysis
12/13/2006	EP1731175A1 Hemostatic polymer useful for rapid blood coagulation and hemostatis
12/13/2006	EP1731171A1 Preventive/remedy for respiratory diseases
12/13/2006	EP1731170A1 Therapeutic agent for diabetes containing insulin resistance improving agent

1 ... 368 369 370 371 372 373 374 375 376 377 378 379 380 381 382 383 384 385 386 387 388 ... 1151